Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Cellebrite Announces Upcoming Investor Events on June 10, 2026

    June 5, 2026

    Uganda Ebola cases rise to 15 after six new infections

    June 3, 2026

    Punjab wildfire chars 3,037 hectares in Kotli Sattian

    June 3, 2026
    Facebook X (Twitter) Instagram
    Zion ChronicleZion Chronicle
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Zion ChronicleZion Chronicle
    Home » MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
    PR Newswire

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    February 14, 2025

    Groundbreaking Technology Combines Recombinant Human Collagen and Hyaluronic Acid for Immediate, Long-Lasting Results

    SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world’s first recombinant human collagen filler, marking a significant breakthrough in skin rejuvenation technology. Utilizing Demulcent™ Type I recombinant collagen, SKINCOLLA offers natural solution for achieving youthful, revitalized skin.

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    Revolutionizing Collagen Filler Technology

    SKINCOLLA is a game-changer in aesthetic treatments. It combines 100% human-identical recombinant collagen with Hyaluronic Acid (HA), providing immediate and lasting improvements to skin texture, elasticity, and hydration. This cutting-edge formula mimics the body’s natural collagen, restoring firmness, smoothness, and addressing common signs of aging such as wrinkles, sagging, and volume loss.

    Why Recombinant Human Collagen?

    Highly Body-Friendly: SKINCOLLA’s recombinant collagen is genetically identical to human collagen, ensuring superior biocompatibility and minimizing the risk of allergic reactions.

    With no synthetic additives, SKINCOLLA ensures optimal rejuvenation, making it a reliable choice for skin enhancement.

    Minimal Pain and No Downtime: Thanks to its structural similarity to natural collagen, SKINCOLLA injections are less painful, and the treatment involves no downtime, allowing patients to return to their daily activities immediately.

    Cultural Sensitivity: SKINCOLLA is designed with respect to diverse cultural and religious preferences, ensuring it’s suitable for patients from all backgrounds, including those adhering to Islamic guidelines.

    Cutting-Edge Technology for Long-Lasting Results

    The proprietary Demulcent™ Type I recombinant collagen in SKINCOLLA is produced in a controlled, high-tech environment. The inclusion of 50mg of HA in the formula further enhances hydration, providing a dual-action solution that amplifies the rejuvenating effects.

    Who Can Benefit from SKINCOLLA?

    SKINCOLLA is ideal for individuals seeking:

    Natural, subtle results without the “overdone” look often associated with traditional fillers.

    Non-invasive skin rejuvenation to improve elasticity, firmness, and hydration.

    Long-term anti-aging benefits, boosting collagen production for sustained skin improvement.

    Indications for SKINCOLLA

    Facial Wrinkles: Neck wrinkles, nasolabial folds, forehead lines, crow’s feet, and marionette lines.

    Eyes: Dark circle reduction, eye wrinkles, and puffiness.

    Body: Skin tightening and brightening in areas such as hands, knees, elbows, and armpits.

    For more information about SKINCOLLA and other products from MAYPHARM CO., LTD., please visit www.maypharm.net or contact sales@maypharm.co.kr.

    Photo – https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/maypharm-co-ltd-launches-skincolla-the-worlds-first-recombinant-human-collagen-filler-for-superior-skin-rejuvenation-302376946.html


    Share. Facebook Twitter Pinterest LinkedIn Telegram Reddit Email

    Related Posts

    Cellebrite Announces Upcoming Investor Events on June 10, 2026

    June 5, 2026

    Getac’s new 8-inch ZX80W and ZX80W-EX tablets blend Windows 11 functionality with energy-efficient fanless design, for all-day productivity in the field

    June 3, 2026

    Coupa Acquires Tonkean to Accelerate Agentic Intake and Orchestration for Global Trade

    May 21, 2026

    Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

    May 20, 2026

    Aitech Awarded $63M Contract for Avionics Computing Solutions to Power India’s Light Combat Helicopter Program

    May 19, 2026

    Cellebrite Announces Participation in Upcoming Investor Conferences

    May 8, 2026
    Latest News

    Uganda Ebola cases rise to 15 after six new infections

    June 3, 2026

    Uganda confirmed six new Ebola cases, raising the outbreak total to 15 as health teams trace contacts and care for admitted patients.

    Punjab wildfire chars 3,037 hectares in Kotli Sattian

    June 3, 2026

    Jangmi disrupts Tokyo flights and rail services

    June 3, 2026

    UAE and IAEA review nuclear safety after Barakah attack

    June 3, 2026

    Tokyo market splits as Nikkei sets closing record

    June 2, 2026

    Eight dead as Türkiye bus strikes highway barrier

    June 1, 2026

    Ebola outbreak in DRC reaches 282 confirmed cases

    June 1, 2026
    © 2026 Zion Chronicle | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.